"Pyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
| Descriptor ID |
D011725
|
| MeSH Number(s) |
D03.383.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridines".
Below are MeSH descriptors whose meaning is more specific than "Pyridines".
This graph shows the total number of publications written about "Pyridines" by people in this website by year, and whether "Pyridines" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 4 | 0 | 4 |
| 1996 | 3 | 5 | 8 |
| 1997 | 4 | 3 | 7 |
| 1998 | 2 | 11 | 13 |
| 1999 | 2 | 13 | 15 |
| 2000 | 3 | 11 | 14 |
| 2001 | 5 | 13 | 18 |
| 2002 | 12 | 20 | 32 |
| 2003 | 11 | 23 | 34 |
| 2004 | 11 | 17 | 28 |
| 2005 | 19 | 15 | 34 |
| 2006 | 18 | 18 | 36 |
| 2007 | 26 | 25 | 51 |
| 2008 | 30 | 29 | 59 |
| 2009 | 25 | 23 | 48 |
| 2010 | 32 | 29 | 61 |
| 2011 | 45 | 32 | 77 |
| 2012 | 45 | 41 | 86 |
| 2013 | 43 | 20 | 63 |
| 2014 | 39 | 34 | 73 |
| 2015 | 35 | 39 | 74 |
| 2016 | 42 | 39 | 81 |
| 2017 | 43 | 20 | 63 |
| 2018 | 37 | 29 | 66 |
| 2019 | 51 | 35 | 86 |
| 2020 | 44 | 37 | 81 |
| 2021 | 46 | 38 | 84 |
| 2022 | 8 | 48 | 56 |
| 2023 | 8 | 15 | 23 |
| 2024 | 24 | 19 | 43 |
Below are the most recent publications written about "Pyridines" by people in Profiles.
-
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. J Immunother Cancer. 2024 Aug 30; 12(8).
-
Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer. Elife. 2024 Aug 30; 13.
-
Entinostat as a combinatorial therapeutic for rhabdomyosarcoma. Sci Rep. 2024 08 15; 14(1):18936.
-
This differentiation block will not stand, man: ivosidenib for MDS. Blood Adv. 2024 Aug 13; 8(15):4207-4208.
-
A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors. Oncologist. 2024 Aug 05; 29(8):721-e1088.
-
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2024 Aug 01; 81(8):749-756.
-
[18F]Flotaza for Aβ Plaque Diagnostic Imaging: Evaluation in Postmortem Human Alzheimer's Disease Brain Hippocampus and PET/CT Imaging in 5xFAD Transgenic Mice. Int J Mol Sci. 2024 Jul 18; 25(14).
-
Characterization of cortico-meningeal translocator protein expression in multiple sclerosis. Brain. 2024 Jul 05; 147(7):2566-2578.
-
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors. J Clin Oncol. 2024 Sep 01; 42(25):3033-3046.
-
A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC. Cancer Res Commun. 2024 Jul 01; 4(7):1850-1862.